Tech Company Financing Transactions
Pyramid Biosciences Funding Round
Pyramid Biosciences, operating out of Waltham, secured $28 million from Adage Capital Management, Averill Master Fund and Prospect Hill Growth Partners.
Transaction Overview
Company Name
Announced On
9/2/2020
Transaction Type
Venture Equity
Amount
$28,000,000
Round
Undisclosed
Proceeds Purpose
The financing will accelerate the growth of Pyramid Biosciences' programs focused on novel tropomyosin receptor kinase (TRK) modulators in oncology and dermatology disorders.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
330 Bear Hill Rd. 302
Waltham, MA 02451
USA
Waltham, MA 02451
USA
Phone
Website
Email Address
Overview
Pyramid Biosciences is dedicated to discovering and developing targeted therapeutics for a wide range of disorders that are regulated by the tropomyosin receptor kinase (TRK) family. By precisely and selectively modulating the actions of these fundamental cell surface receptors, we can control the key signaling pathways responsible for a patient's disease, condition, or symptoms.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Kollol Pal
VP - Bus. Development
Jordan Leef
Browse more venture capital transactions:
Prev: 9/2/2020: Capchase venture capital transaction
Next: 9/2/2020: Sarcos Robotics venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs